Want to see IN:IPCALAB full AI Analyst Report?
IPCALAB Stock Chart & Stats
₹1762.70
₹14.90(0.85%)
At close: 4:00 PM EDT
₹1762.70
₹14.90(0.85%)
Day’s Range― - ―
52-Week Range₹1,252.95 - ₹1,945.00
Previous CloseN/A
Volume119.64K
Average Volume (3M)6.78K
Market Cap
₹477.74B
Enterprise Value₹417.40K
Total Cash (Recent Filing)₹11.98B
Total Debt (Recent Filing)₹8.09B
Price to Earnings (P/E)36.5
Beta0.20
Next Earnings
Nov 06, 2026Next Dividend Ex-DateN/A
Dividend Yield0.32%
Share Statistics
EPS (TTM)44.98
Shares Outstanding253,659,230
10 Day Avg. Volume6,645
30 Day Avg. Volume6,776
Financial Highlights & Ratios
PEG Ratio0.65
Price to Book (P/B)5.04
Price to Sales (P/S)4.21
P/FCF Ratio83.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)59.07
Revenue Forecast (FY)₹109.74B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage reduces financial risk and interest burden, giving IPCA flexibility to fund capacity, compliance, research, or working-capital needs. The improvement from prior years also provides resilience if pharmaceutical demand or margins weaken.
Healthy Profitability And ScaleIPCA has built meaningful operating scale while retaining healthy profitability across APIs and finished formulations. This supports reinvestment and indicates that its integrated manufacturing and product portfolio can generate earnings beyond simple volume growth.
Positive Operating Cash GenerationPositive operating and free cash flow shows that the business converts its pharmaceutical operations into internally generated funds. This supports capital investment and reduces reliance on external financing, particularly alongside the company’s conservative debt position.
Bears Say
Slowing Revenue GrowthThe moderation in top-line growth suggests that recent expansion has become less dynamic. Sustained slower growth could limit operating leverage and make future earnings increasingly dependent on pricing, product mix, productivity, or new market and product opportunities.
Margin CompressionLower margins indicate pressure from costs, pricing, competition, or a less favorable mix across APIs and formulations. If the compression persists, revenue growth may translate into weaker earnings growth and reduce the returns generated from the company’s expanded asset base.
Moderate Free Cash Flow ConversionAlthough cash generation is positive, only a moderate portion of accounting profit becomes free cash flow. Working-capital requirements or capital expenditure are absorbing earnings, which can constrain reinvestment, dividends, or balance-sheet flexibility if this pattern persists.
IPCA Laboratories Limited News
IPCALAB FAQ
What was IPCA Laboratories Limited’s price range in the past 12 months?
IPCA Laboratories Limited lowest stock price was ₹1252.95 and its highest was ₹1945.00 in the past 12 months.
What is IPCA Laboratories Limited’s market cap?
IPCA Laboratories Limited’s market cap is ₹477.74B.
When is IPCA Laboratories Limited’s upcoming earnings report date?
IPCA Laboratories Limited’s upcoming earnings report date is Nov 06, 2026 which is in 79 days.
How were IPCA Laboratories Limited’s earnings last quarter?
IPCA Laboratories Limited released its earnings results on Aug 13, 2026. The company reported ₹15.84 earnings per share for the quarter, beating the consensus estimate of ₹12.162 by ₹3.678.
Is IPCA Laboratories Limited overvalued?
According to Wall Street analysts IPCA Laboratories Limited’s price is currently Overvalued.
Does IPCA Laboratories Limited pay dividends?
IPCA Laboratories Limited pays a Annually dividend of ₹6 which represents an annual dividend yield of 0.32%. See more information on IPCA Laboratories Limited dividends here
What is IPCA Laboratories Limited’s EPS estimate?
IPCA Laboratories Limited’s EPS estimate is 14.
How many shares outstanding does IPCA Laboratories Limited have?
IPCA Laboratories Limited has 253,659,230 shares outstanding.
What happened to IPCA Laboratories Limited’s price movement after its last earnings report?
IPCA Laboratories Limited reported an EPS of ₹15.84 in its last earnings report, beating expectations of ₹12.162. Following the earnings report the stock price went up 1.692%.
Which hedge fund is a major shareholder of IPCA Laboratories Limited?
Currently, no hedge funds are holding shares in IN:IPCALAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IPCA Laboratories Limited
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Technical Analysis
Ajanta Pharma Limited
―
Emcure Pharmaceuticals Limited
―
―
Neuland Laboratories Ltd.
―
Wockhardt Limited
―